“Low Dose MR” Dixon Technique for Imaging FDG PET-MR Lymphoma

Abstract

Introduction Hybrid PET-MR is a relatively new imaging modality with its major strength being the MR component offering superior soft tissue contrast. While PET/MRI offers the inherent advantage of reduced radiation dose, it has been shown to result in a markedly prolonged examination time becoming a challenge in children and sick patients. "Low dose MRI" is a term used in the nuclear medicine community to describe fast acquired PET-MR scan protocols that rely heavily on PET images for diagnosis. In this study, we sought to determine if the Dixon sequences obtained for attenuation correction could be used as a diagnostic sequence for interpreting PET-MRI lymphoma cases, potentially reducing scan time.

Materials and Methods We retrospectively identified 40 patients who underwent ⁸⁸FDG PET-MR body imaging studies for staging or restaging lymphoma. A radiologist and nuclear medicine physician initially reviewed top of the head to mid thigh PET images, attenuation correction coronal Dixon MRI sequences, and PET-MR fusion with Dixon sequence. The same physicians reviewed the PET images, multi-sequence MR including the attenuation correction Dixon, and multi-sequence PET-MR fusion images The lesions were further characterized based on their imaging characteristics, size, SUVmax, and malignant potency. A consensus read followed.

Results  All patients were adults with an average study age of 43.8 years. Our study consisted of 40 females and 48 males out of which 7 were for staging and 81 were for re-staging. All patients had systemic lymphoma. Thirty-seven of the studies had active lymph nodes on Dixon PET-MR that agreed with multi-sequence PET-MR which identified 33 positive cases (89.1%) having an average SUV 10.2 ± 7.74 SD. Four Dixon PET-MR cases did not detect lesions, with an average SUV 2.3 ± 0.55 SD, which was read as minimal residual activity. Multi-sequence MR identified 11 patients with enlarged lymph nodes without FDG uptake, which were not seen on Dixon MR. All 5 studies with bones lesions were detected by Dixon PET-MR as well as 2 soft tissue organ lesions. Multi-sequence MR identified 1 patient with non-active, healed bone lesion. Fifty-five of these studies were true negatives. Compared to multi-sequence PET-MR, Dixon PET-MR demonstrated 89.2% sensitivity, 100% specificity with no false positive studies.

Conclusion  The present study investigated the diagnostic potential of a fast protocol for integrated PET/MRI used for dedicated tumor staging of patients with lymphoma. In this retrospective study, Dixon PET-MR was shown to be sensitive and specific compared to multi-sequence PET-MR in the detection of lymphoma. The low number of these cases not detected had minimally active lymph nodes that resolved on subsequent imaging and probably were not clinically important.

Keywords - Dixon sequence - PET-MR - lymphoma - FDG - multi-sequence MR

Publikationsverlauf

Artikel online veröffentlicht:
19. Juli 2022

• References

• 1 Brent RL. Saving lives and changing family histories: appropriate counseling of pregnant women and men and women of reproductive age, concerning the risk of diagnostic radiation exposures during and before pregnancy. Am J Obstet Gynecol 2009; 200 (01) 4-24
• 2 Frampas E. Lymphomas: basic points that radiologists should know. Diagn Interv Imaging 2013; 94 (02) 131-144
• 3 Johnson SA, Kumar A, Matasar MJ, Schöder H, Rademaker J. Imaging for staging and response assessment in lymphoma. Radiology 2015; 276 (02) 323-338
• 4 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67 (01) 7-30
• 5 Biko DM, Anupindi SA, Hernandez A, Kersun L, Bellah R. Childhood Burkitt lymphoma: abdominal and pelvic imaging findings. AJR Am J Roentgenol 2009; 192 (05) 1304-1315
• 6 Toma P, Granata C, Rossi A, Garaventa A. Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. Radiographics 2007; 27 (05) 1335-1354
• 7 Jaimes C, Kirsch JE, Gee MS. Fast, free-breathing and motion-minimized techniques for pediatric body magnetic resonance imaging. Pediatr Radiol 2018; 48 (09) 1197-1208
• 8 Arlachov Y, Ganatra RH. Sedation/anaesthesia in paediatric radiology. Br J Radiol 2012; 85 (1019): e1018-e1031
• 9 Wilder RT, Flick RP, Sprung J. et al. Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology 2009; 110 (04) 796-804
• 10 Moog F, Bangerter M, Diederichs CG. et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203 (03) 795-800
• 11 Ngeow JYY, Quek RHH, Ng DCE. et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol 2009; 20 (09) 1543-1547
• 12 Bruzzi JF, Macapinlac H, Tsimberidou AM. et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006; 47 (08) 1267-1273
• 13 Zhou HY, Gao F, Bu B. et al. Primary bone lymphoma: a case report and review of the literature. Oncol Lett 2014; 8 (04) 1551-1556
• 14 Afaq A, Fraioli F, Sidhu H. et al. Comparison of PET/MRI with PET/CT in the evaluation of disease status in lymphoma. Clin Nucl Med 2017; 42 (01) e1-e7
• 15 Ricci ZJ, Kaul B, Stein MW. et al. Improving diagnosis of atraumatic splenic lesions, Part III: malignant lesions. Clin Imaging 2016; 40 (05) 846-855
• 16 Kim JH, Lee SH, Park J. et al. Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol 2004; 34 (09) 510-514
• 17 Ehman EC, Johnson GB, Villanueva-Meyer JE. et al. PET/MRI: where might it replace PET/CT?. J Magn Reson Imaging 2017; 46 (05) 1247-1262
• 18 Martin O, Schaarschmidt BM, Kirchner J. et al. PET/MRI versus PET/CT for whole-body staging: results from a single-center observational study on 1,003 sequential examinations. J Nucl Med 2020; 61 (08) 1131-1136
• 19 Mayerhoefer ME, Prosch H, Beer L. et al. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging 2020; 47 (01) 51-60
• 20 Kirchner J, Sawicki LM, Suntharalingam S. et al. Whole-body staging of female patients with recurrent pelvic malignancies: ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT. PLoS One 2017; 12 (02) e0172553
• 21 Sher AC, Seghers V, Paldino MJ. et al. Assessment of sequential PET/MRI in comparison with PET/CT of pediatric lymphoma: a prospective study. AJR Am J Roentgenol 2016; 206 (03) 623-631
• 22 Grueneisen J, Sawicki LM, Schaarschmidt BM. et al. Evaluation of a fast protocol for staging lymphoma patients with integrated PET/MRI. PLoS One 2016; 11 (06) e0157880
• 23 Jeong JH, Cho IH, Kong EJ, Chun KA. Evaluation of Dixon sequence on hybrid PET/MR compared with contrast-enhanced PET/CT for PET-positive lesions. Nucl Med Mol Imaging 2014; 48 (01) 26-32
• 24 Cheson BD, Fisher RI, Barrington SF. et al; Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27) 3059-3068
• 25 Kim YW, Mansfield LT. Fool me twice: delayed diagnoses in radiology with emphasis on perpetuated errors. AJR Am J Roentgenol 2014; 202 (03) 465-470
• 26 Braunstein S, Nakamura JL. Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Front Oncol 2013; 3: 73